BRPI0812134A2 - Anatagonistas de cxcr4 de peptídio cíclico - Google Patents

Anatagonistas de cxcr4 de peptídio cíclico

Info

Publication number
BRPI0812134A2
BRPI0812134A2 BRPI0812134-6A2A BRPI0812134A BRPI0812134A2 BR PI0812134 A2 BRPI0812134 A2 BR PI0812134A2 BR PI0812134 A BRPI0812134 A BR PI0812134A BR PI0812134 A2 BRPI0812134 A2 BR PI0812134A2
Authority
BR
Brazil
Prior art keywords
anatagonists
cxcr4
cyclic peptide
peptide
cyclic
Prior art date
Application number
BRPI0812134-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Wayne David Kohn
Shebg-Bin Peng
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812134(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0812134A2 publication Critical patent/BRPI0812134A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0812134-6A2A 2007-05-30 2008-05-20 Anatagonistas de cxcr4 de peptídio cíclico BRPI0812134A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31
PCT/US2008/064177 WO2008150689A1 (en) 2007-05-30 2008-05-20 Cyclic peptide cxcr4 antagonists

Publications (1)

Publication Number Publication Date
BRPI0812134A2 true BRPI0812134A2 (pt) 2014-11-18

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812134-6A2A BRPI0812134A2 (pt) 2007-05-30 2008-05-20 Anatagonistas de cxcr4 de peptídio cíclico

Country Status (32)

Country Link
US (3) US7691813B2 (OSRAM)
EP (2) EP2160221B1 (OSRAM)
JP (1) JP5358564B2 (OSRAM)
KR (2) KR101169846B1 (OSRAM)
CN (1) CN101678213B (OSRAM)
AR (1) AR066648A1 (OSRAM)
AT (1) ATE516853T1 (OSRAM)
AU (1) AU2008260326B2 (OSRAM)
BR (1) BRPI0812134A2 (OSRAM)
CA (1) CA2688574C (OSRAM)
CL (1) CL2008001467A1 (OSRAM)
CO (1) CO6241137A2 (OSRAM)
CR (1) CR11105A (OSRAM)
CY (1) CY1111815T1 (OSRAM)
DK (1) DK2160221T3 (OSRAM)
DO (1) DOP2009000270A (OSRAM)
EA (1) EA017716B1 (OSRAM)
GT (1) GT200900304A (OSRAM)
HR (1) HRP20110551T1 (OSRAM)
IL (1) IL201685A (OSRAM)
JO (1) JO2776B1 (OSRAM)
MA (1) MA31666B1 (OSRAM)
MX (1) MX2009012952A (OSRAM)
MY (1) MY149432A (OSRAM)
NZ (1) NZ580849A (OSRAM)
PE (1) PE20090299A1 (OSRAM)
PL (1) PL2160221T3 (OSRAM)
PT (1) PT2160221E (OSRAM)
TN (1) TN2009000496A1 (OSRAM)
TW (1) TWI423987B (OSRAM)
WO (1) WO2008150689A1 (OSRAM)
ZA (1) ZA200908345B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JPWO2012118124A1 (ja) * 2011-03-01 2014-07-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
CA2838037C (en) * 2011-06-07 2019-09-17 Polyphor Ag Beta-hairpin peptidomimetics as cxc4 antagonists
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN109922818B (zh) * 2016-09-06 2024-02-20 主线生物科学公司 Cxcr4拮抗剂及使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
CA3065086A1 (en) * 2017-09-05 2019-03-14 Mainline Biosciences High affinity cxcr4 selective binding conjugate and method for using the same
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Cxcr4結合性化合物もしくはその塩またはそれらと金属との錯体
EA202190755A1 (ru) 2018-09-12 2021-06-11 Технише Универзитет Мюнхен Агенты для терапии и диагностики рака
WO2020053256A1 (en) 2018-09-12 2020-03-19 Technische Universität München Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
EP4232459A4 (en) * 2020-10-21 2024-12-04 Provincial Health Services Authority NEW COMPOUNDS TARGETING CXCR4
US20240124517A1 (en) * 2020-12-25 2024-04-18 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound containing n-substituted-amino acid residue
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
JP2025513489A (ja) * 2022-04-20 2025-04-24 プロビンシャル・ヘルス・サービシーズ・オーソリティ Cxcr4標的化合物、およびその作製方法、およびその使用方法
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規cxcr4アンタゴニスト
US8628750B2 (en) * 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment

Also Published As

Publication number Publication date
PT2160221E (pt) 2011-09-12
KR101319740B1 (ko) 2013-10-17
JO2776B1 (en) 2014-03-15
HK1141474A1 (en) 2010-11-12
JP2010529957A (ja) 2010-09-02
CA2688574C (en) 2014-02-18
CY1111815T1 (el) 2015-10-07
NZ580849A (en) 2012-03-30
AU2008260326B2 (en) 2011-07-21
USRE42274E1 (en) 2011-04-05
KR101169846B1 (ko) 2012-08-01
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
KR20100003737A (ko) 2010-01-11
TW200902556A (en) 2009-01-16
EP2377579A1 (en) 2011-10-19
GT200900304A (es) 2011-11-09
PL2160221T3 (pl) 2011-12-30
MX2009012952A (es) 2009-12-11
US20100130409A1 (en) 2010-05-27
AU2008260326A1 (en) 2008-12-11
IL201685A (en) 2015-04-30
JP5358564B2 (ja) 2013-12-04
CN101678213A (zh) 2010-03-24
CO6241137A2 (es) 2011-01-20
PE20090299A1 (es) 2009-03-19
ATE516853T1 (de) 2011-08-15
TWI423987B (zh) 2014-01-21
EA017716B1 (ru) 2013-02-28
MA31666B1 (fr) 2010-09-01
CA2688574A1 (en) 2008-12-11
EP2160221B1 (en) 2011-07-20
CR11105A (es) 2010-04-12
CL2008001467A1 (es) 2008-12-05
US7691813B2 (en) 2010-04-06
IL201685A0 (en) 2010-05-31
EP2160221A1 (en) 2010-03-10
AR066648A1 (es) 2009-09-02
MY149432A (en) 2013-08-30
DOP2009000270A (es) 2010-01-15
EA200971129A1 (ru) 2010-04-30
TN2009000496A1 (en) 2011-03-31
US20080300177A1 (en) 2008-12-04
DK2160221T3 (da) 2011-09-19
HRP20110551T1 (hr) 2011-09-30
CN101678213B (zh) 2013-11-06
WO2008150689A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
BRPI0812134A2 (pt) Anatagonistas de cxcr4 de peptídio cíclico
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0814587A2 (pt) Peptídeos antibióticos
BRPI0817927A2 (pt) Comprimidos orodispersiveis
DK3115370T3 (da) Biologisk aktive peptider
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
BRPI0918948A2 (pt) macrociclos peptidomiméticos
BRPI0911743A2 (pt) "peptídeo"
DK2274030T4 (da) Lægemiddelafgivelsesanordning
EP2504351A4 (en) MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
EP2165942A4 (en) Plug structure
BRPI0918833A2 (pt) macrociclos peptidomiméticos
DE602007003060D1 (de) Anodische Bindungsvorrichtung
BRPI1012728A2 (pt) uso de tripeptídeos
ZA201000776B (en) Cyclic depsipeptides
BRPI0922842A2 (pt) prendedor com grampo antirrotação
BRPI0814876A2 (pt) Análogos de pirona fosforilados e métodos
EP2236266A4 (en) Injector
DE502008001632D1 (de) Karosserieaufbau
BRPI1010661A2 (pt) peptídeo
DK2381976T3 (da) Lægemiddeladministrationsanordning
BRPI0922716A2 (pt) purificação de polipeptídeo
EP2101804A4 (en) PROANGIOGENIC PEPTIDES
BRPI0820750A2 (pt) Proteína cíclica isenta de cisteínas
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]